melanoma

News

Moderna looks to its post-COVID growth prospects

With sales of its COVID-19 vaccines on the wane, Moderna has showcased the projects it will look to for the next phase of its development, headed by new vaccines for influ

News

MSD, Moderna start phase 3 trial of mRNA cancer jab

MSD & Co and Moderna have advanced a combination of an mRNA-based cancer vaccine and checkpoint inhibitor Keytruda into a phase 3 trial in skin cancer melanoma, althou

News

ASCO: Moderna, Merck melanoma vaccine set for phase 3

Moderna’s move into personalised cancer therapy continues to proceed at a rapid pace, with Merck & Co-partnered melanoma vaccine mRNA-4157 heading for a pivotal phase

News

Iovance eyes November FDA decision on melanoma cell therapy

Iovance Biotherapeutics could be a few months away from a first regulatory approval for lifileucel, which could be the first cell-based therapy for a solid tumour in the U

News

Merck, Moderna cue up phase 3 trials for mRNA cancer shot

Moderna and partner Merck & Co have fleshed out the data from their clinical trial of personalised mRNA vaccine for melanoma, saying the results support the start of a

News

Phase 3 setbacks mar Eisai, Merck’s cancer alliance

Two late-stage trials combining Merck & Co’s cancer immunotherapy Keytruda with Eisai’s targeted cancer drug Lenvima have generated disappointing results in hard-to-tr

Moderna looks to its post-COVID growth prospects

MSD, Moderna start phase 3 trial of mRNA cancer jab

ASCO: Moderna, Merck melanoma vaccine set for phase 3

Iovance eyes November FDA decision on melanoma cell therapy

Merck, Moderna cue up phase 3 trials for mRNA cancer shot

Phase 3 setbacks mar Eisai, Merck’s cancer alliance

Late-breakers to look out for at ASCO 2026

Discover a new era of healthcare panel engagement: Grounded ...

melanoma

Editor's Picks